CATALAYER NEWS
FDA Approves Arcutisâ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
Source: BI Markets · 2026-06-29
Full article text is available in the Catalayer news terminal.
RELATED ON CATALAYER
Related Topics
Biotech & FDA NewsRELATED MARKETS
Prediction Markets